Reviewed clinical summary · Source-linked · Educational use only

Three Virtual Diabetes Self-Management Programs All Lowered A1c in Texas

Hormone Insight clinical visual abstract for article 3379

Clinical Bottom Line

A three-arm randomized trial in Texans with uncontrolled type 2 diabetes found that all three self-paced virtual and technology-based self-management programs significantly reduced A1c, with no in-person comparator. PICO summary and expert commentary.

Summary: In a three-arm randomized controlled trial of adults with uncontrolled type 2 diabetes in rural and urban Texas, three self-paced delivery formats were compared with one another: an asynchronous virtual education programme with one-on-one counselling (vMMWD), a technology-based education and support programme (TBES), and a combined sequence of both. All three arms produced statistically significant reductions in A1c that were already present at three months and sustained at six months, with consistent effects across rural and urban participants. The trial did not include an in-person or usual-care comparator, and the abstract does not report the magnitude of the A1c change, confidence intervals, or between-arm differences.

PICO Summary

ElementDetail
PopulationAdults with uncontrolled type 2 diabetes living in rural and urban Texas, United States. Three-arm randomized controlled trial, intent-to-treat, conducted November 2020 to March 2022.
InterventionSelf-paced virtual modalities: (1) asynchronous virtual education plus one-on-one follow-up counselling (virtual Making Moves with Diabetes, vMMWD); (2) technology-based education and support (TBES); (3) combined sequential vMMWD then TBES. Per-arm sample sizes not reported in the abstract.
ComparisonThe three delivery formats were compared against one another. There was no in-person, group-based, or usual-care control arm.
OutcomePrimary outcome A1c, assessed at baseline, 3 and 6 months using constrained longitudinal data analysis. All three arms produced statistically significant A1c reductions; 3-month reductions were sustained at 6 months and were consistent across rural and urban participants. The abstract does not report effect size, 95% CI, p-values, or ARR/NNT.

Expert Commentary

This randomized trial offers reasonably encouraging evidence that self-paced virtual diabetes self-management programmes can lower A1c in a population that often struggles to access in-person education, and the persistence of the effect from three to six months across both rural and urban participants is a genuine strength. The verdict, however, must stay measured. Because all three arms were active virtual interventions, the design tells us that these formats are broadly comparable to each other, not that any one is superior, and the absence of an in-person or usual-care comparator means we cannot quantify how much better virtual delivery is than standard care or no intervention. The single most important limitation is that the abstract reports no effect magnitude, confidence intervals, or between-arm contrasts, so the clinical size of the A1c benefit remains unknown from these data alone. Can I use this with my patients? For motivated adults with uncontrolled type 2 diabetes who face geographic or scheduling barriers to in-person education, a structured virtual programme is a reasonable option to offer alongside, not in place of, usual clinical care. The earlier framing that virtual education beat in-person education is not supported and should be set aside. I would like to see the full paper report the absolute A1c changes and head-to-head statistics before drawing firmer conclusions about which format to prioritise.

References

Ory MG, Han G, Nsobundu C, Carpenter K, Towne SD, Smith ML. Comparative effectiveness of diabetes self-management education and support intervention strategies among adults with type 2 diabetes in Texas. Front Public Health. 2025;13:1543298. doi:10.3389/fpubh.2025.1543298

Educational use: Hormone Insight is intended for healthcare professionals and learners. Interpret each summary alongside the primary source, local guidance, and patient-specific clinical judgement.

Subscribe now

Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.

© 2024-2026 Hormone Insight. All rights reserved.